Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an announcement.
Hemogenyx Pharmaceuticals has raised £2.5 million through a direct subscription of 313,333 new shares at £7.50 each from a consortium of private investors, accompanied by three-year warrants exercisable at £9. The funds will primarily support continuation and dose escalation of its Phase I clinical trial of HG-CT-1, a CAR-T therapy for relapsed or refractory acute myeloid leukemia in adults, and the launch of an FDA-cleared Phase I trial in pediatric patients aged 12 to 18.
To conserve cash, the company has outsourced manufacturing of HG-CT-1 to specialist contractor Made Scientific and is finalizing technology transfer to supply both adult and pediatric cohorts, while also progressing its CDX and CBR pipelines where feasible. Following admission of the new shares to the London Stock Exchange’s Main Market, Hemogenyx’s enlarged share capital will total 6,354,588 ordinary shares, positioning the company with additional runway to execute its clinical program and potentially strengthen its standing in the AML treatment landscape.
The most recent analyst rating on (GB:HEMO) stock is a Hold with a £725.00 price target. To see the full list of analyst forecasts on HemoGenyx Pharmaceuticals Plc stock, see the GB:HEMO Stock Forecast page.
Spark’s Take on GB:HEMO Stock
According to Spark, TipRanks’ AI Analyst, GB:HEMO is a Neutral.
The score is held down primarily by very weak financial performance (no revenue, ongoing losses and cash burn, and higher balance-sheet risk from lower equity and increased leverage). Technicals provide some offset with strong recent momentum, but overbought indicators add near-term risk, and valuation support is limited due to a negative P/E and no dividend yield.
To see Spark’s full report on GB:HEMO stock, click here.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a London-headquartered, clinical-stage biopharmaceutical company listed on the LSE and focused on developing new medicines for blood and autoimmune diseases. The group, which operates through U.S. subsidiaries in New York, is advancing multiple complementary product candidates and platform technologies to drive novel drug development.
Average Trading Volume: 44,007
Technical Sentiment Signal: Strong Buy
Current Market Cap: £66.45M
For detailed information about HEMO stock, go to TipRanks’ Stock Analysis page.